Tag : England

Latest News

Investigation of the impact of the NICE guidelines regarding antibiotic prophylaxis during invasive dental procedures on the incidence of infective endocarditis in England: an Electronic Health Records study

Newsemia
Quan, P; Muller-Pebody, B; Fawcett, N; Young, B; MINAJI, M; Sandoe, J; Hopkins, S; … Walker, A; + view all Quan, P; Muller-Pebody, B; Fawcett,...
Latest News

Towards school autonomy in England: A troubled and far from complete journey

Newsemia
Male, T; (2019) Towards school autonomy in England: A troubled and far from complete journey. In: Rauscher, E and Wiesner, C and Paasch, D and...
Latest News

Comparing socio-economic inequalities in healthy ageing in the United States of America, England, China and Japan: evidence from four longitudinal studies of ageing

Newsemia
Lu, W; Pikhart, H; Sacker, A; (2019) Comparing socio-economic inequalities in healthy ageing in the United States of America, England, China and Japan: evidence from...
Latest News

Changing fortunes? Aspiration and realisation for looked after young people’s post-compulsory educational pathways in England

Newsemia
Cameron, CL; (2018) Changing fortunes? Aspiration and realisation for looked after young people’s post-compulsory educational pathways in England. Longitudinal and Life Course Studies , 9...
Latest News

Samenvatting: Resultaten van Fase III SAkuraSky-studie voor Chugai’s Satralizumab bij Neuromyelitis Optica Spectrumstoornis Gepubliceerd in The New England Journal of Medicine Online

Newsemia
TOKYO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) heeft aangekondigd dat de resultaten van de SAkuraSky-studie (NCT02028884), een wereldwijde fase III klinische studie van satralizumab (ontwikkelingscode:...
Latest News

Positive Phase III Results for Genentech’s Satralizumab in Neuromyelitis Optica Spectrum Disorder Published in the New England Journal of Medicine

Newsemia
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that data from SAkuraSky, a pivotal Phase...
Latest News

Die Ergebnisse der Phase-III-SAkuraSky-Studie für Chugai Satralizumab bei Neuromyelitis-optica-Spektrum-Erkrankungen wurden im New England Journal of Medicine Online veröffentlicht

Newsemia
TOKIO (Japan)–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) gab bekannt, dass die Ergebnisse der SAkuraSky-Studie (NCT02028884), einer globalen klinischen Phase-III-Studie zu Satralizumab (Entwicklungscode: SA237), am...
Latest News

Les résultats d’une étude SAkuraSky de phase III portant sur le satralizumab de Chugai pour la maladie du spectre de la neuromyélite optique ont été publiés en ligne dans le New England Journal of Medicine

Newsemia
TOKYO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO : 4519) a annoncé que les résultats de l’étude SAkuraSky (NCT02028884), une étude clinique mondiale de phase III portant sur le satralizumab (code...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy